Oral delivery of insulin using ligand-directed nanoparticles that do not compete with physiological ligands
使用不与生理配体竞争的配体导向纳米颗粒口服胰岛素
基本信息
- 批准号:10373829
- 负责人:
- 金额:$ 37.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:Active Biological TransportAddressAdoptionAffectAffinityAnxietyApicalApoptosisBeta CellBindingBinding SitesBioavailableBiodistributionBiologicalBiological AvailabilityBiological ModelsBlood GlucoseCarbohydratesCell LineCell Surface ReceptorsCell physiologyCell surfaceCenters for Disease Control and Prevention (U.S.)ChemistryChronicClinicalClinical ResearchCommunitiesComplexCoronary heart diseaseDiabetes MellitusDipeptidyl-Peptidase IVDiseaseDosage FormsDoseDrug CarriersDrug Delivery SystemsDrug DesignDrug KineticsEncapsulatedEpithelialExcipientsFastingFoodFormulationFoundationsFrightFunctional disorderGastrointestinal tract structureGlucoseGlycosylated hemoglobin AGoalsGrantHealth ProfessionalHigh Fat DietHypoglycemiaIn VitroInflammationInjectionsInsulinInsulin-Dependent Diabetes MellitusInterventionIntestinal AbsorptionIntestinesIronKidneyKidney DiseasesKnowledgeLeadLengthLigandsLiteratureMammalian CellMediatingMedicineMicrovascular DysfunctionModelingMolecular WeightMucous body substanceNeedlesNeuropathyNon-Insulin-Dependent Diabetes MellitusNucleosome Core ParticleOralOral AdministrationOutcomePainPathogenicityPatient NoncompliancePatientsPeptide HydrolasesPerceptionPerformancePharmaceutical PreparationsPharmacologic SubstancePhysiciansPhysiologicalPolyestersPolymersRattusReportingResortRetinal DiseasesRoleScheduleSodiumStomachStrokeSurfaceSystemTFRC geneTabletsTechnologyTestingTherapeuticTimeToxic effectTransferrinUnited KingdomWeight GainWorkabsorptionamphiphilicityanalogcapsulecardiovascular disorder riskcompliance behaviordensitydiabetic ratdrug dispositiondrug efficacyexperiencegambogic acidglucagon-like peptide 1hepatic gluconeogenesisimprovedin vivoin vivo Modelinhibitor/antagonistinsulin secretioninsulin sensitivityintestinal barriermacrovascular diseasenanoparticlenanoscalenanosystemsnovelpreventprospectivepsychologicreceptorreceptor bindingsecretion processside effectstemtherapy outcome
项目摘要
Project Summary
The primary focus of managing type 2 diabetes (T2D) has traditionally been the strict control of blood glucose
using one or multiple orally administered medications. Drugs currently used to treat T2D range from
pharmaceutical agents that increase insulin secretion or sensitivity, to those that decrease hepatic
gluconeogenesis or intestinal carbohydrate absorption. Agents that are more recent include glucagon-like
peptide-1 (GLP-1) analogues, which inhibit the breakdown of endogenous GLP-1 by dipeptidyl peptidase-IV
(DPP-IV), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, which block normal glucose reabsorption in
the kidneys. According to the United Kingdom Prospective Diabetes Study (UKPDS 33), even though the efficacy
of these drugs in preventing microvascular complications of T2D (e.g., retinopathy, neuropathy and nephropathy)
has been partially established, their role in preventing macrovascular complications (e.g., coronary heart disease
and stroke) remains elusive. Moreover, the same study points out that 50 percent of patients originally controlled
with a single drug acquired tolerance and needed the addition of a second drug after three years, and by nine
years, about 75 percent of patients needed multiple therapies to achieve the target HbA1c value. There is
significant evidence that in some T2D patients, despite taking medications, the β-cell function undergoes
continuous decline and eventually fails entirely, leaving these patients the only option of insulin therapy. Rather
than being used as a treatment of last resort however, the clinical and research communities are recognizing
that early initiation of insulin therapy in T2D patients will correct all of the underlying pathogenic mechanisms
such as increased β-cell apoptosis, glucotoxicity, lipotoxicity, and inflammation. Major drawbacks of early insulin
injections for T2D include risks of cardiovascular disease, weight gain and hypoglycemia, stemming from
irregular or incorrect dosing, lack of time in the physician's schedule to manage insulin therapy, and most
importantly, patient non-compliance. Successful oral delivery of insulin is therefore a therapeutic Holy Grail as
its inherent ease of administration mimicking natural secretion process potentially obviates or minimizes many
of the drawbacks, and should reduce much of the burden of managing T2D by health care professionals.
However, gastric instability and lack of transport across tightly packed epithelium and overlying mucus are
formidable challenges to successful intestinal absorption of insulin. The work enabled by previous findings, in
which oral delivery of insulin using ligand-directed nanoparticles that do not compete with physiological ligands
led to improved therapeutic outcomes compared to conventional nanoparticles. In this project, the technology is
further developed by investigating, how fine-tuning the nanoparticle composition affect the drug disposition and
therapeutic outcomes, under the influence of commonly experienced physiological and pathophysiology
conditions. In doing so, the project will establish 1) optimal non-competitive nanoparticle chemistry, 2) active
drug delivery under pertinent physiological conditions, and 3) the therapeutic window of oral insulin in T2D.
项目摘要
传统上,管理2型糖尿病(T2 D)的主要焦点是严格控制血糖
使用一种或多种口服药物。目前用于治疗T2 D的药物范围从
增加胰岛素分泌或敏感性的药剂,至降低肝胰岛素分泌或敏感性的药剂。
肠道碳水化合物的吸收。最近的药物包括胰高血糖素样
肽-1(GLP-1)类似物,其抑制内源性GLP-1被二肽基肽酶-IV分解
(DPP-IV)和钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制剂,其阻断正常的葡萄糖重吸收,
肾脏根据英国前瞻性糖尿病研究(UKPDS 33),即使疗效
这些药物在预防T2 D的微血管并发症中的作用(例如,视网膜病变、神经病变和肾病)
已经部分确定,它们在预防大血管并发症中的作用(例如,冠心病
和中风)仍然难以捉摸。此外,同一项研究指出,50%的患者最初控制
用一种药物获得耐受性,三年后需要添加第二种药物,
大约75%的患者需要多种治疗才能达到目标HbA 1c值。有
有重要证据表明,在一些T2 D患者中,尽管服用药物,β细胞功能仍发生了变化,
持续下降并最终完全失败,使这些患者成为胰岛素治疗的唯一选择。而
然而,临床和研究界都认识到,
在T2 D患者中早期开始胰岛素治疗将纠正所有潜在的致病机制
如β细胞凋亡增加、葡萄糖毒性、脂毒性和炎症。早期胰岛素的主要缺点
注射T2 D包括心血管疾病、体重增加和低血糖的风险,
不规则或不正确的剂量,医生的时间表中缺乏时间来管理胰岛素治疗,以及大多数
更重要的是,患者不服从。因此,胰岛素的成功口服递送是治疗的圣杯,
其模仿天然分泌过程固有的给药容易性潜在地消除或最小化了许多
的缺点,并应减少医疗保健专业人员管理T2 D的负担。
然而,胃的不稳定性和缺乏运输通过紧密包装的上皮和覆盖的粘液,
胰岛素的成功肠道吸收的巨大挑战。这项工作使以前的调查结果,在
所述口服递送使用不与生理配体竞争的配体导向的纳米颗粒
与传统的纳米颗粒相比,导致了改善的治疗效果。在这个项目中,
通过研究进一步开发,微调纳米颗粒组合物如何影响药物处置,
在常见生理和病理生理学影响下的治疗结局
条件在这样做的过程中,该项目将建立1)最佳的非竞争性纳米粒子化学,2)活性
在相关生理条件下的药物递送,和3)T2 D中口服胰岛素的治疗窗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Raghu Ganugula其他文献
Raghu Ganugula的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Raghu Ganugula', 18)}}的其他基金
Oral delivery of insulin using ligand-directed nanoparticles that do not compete with physiological ligands
使用不与生理配体竞争的配体导向纳米颗粒口服胰岛素
- 批准号:
10399664 - 财政年份:2020
- 资助金额:
$ 37.25万 - 项目类别:
Oral delivery of insulin using ligand-directed nanoparticles that do not compete with physiological ligands
使用不与生理配体竞争的配体导向纳米颗粒口服胰岛素
- 批准号:
10580808 - 财政年份:2020
- 资助金额:
$ 37.25万 - 项目类别:
Oral delivery of insulin using ligand-directed nanoparticles that do not compete with physiological ligands
使用不与生理配体竞争的配体导向纳米颗粒口服胰岛素
- 批准号:
10027854 - 财政年份:2020
- 资助金额:
$ 37.25万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 37.25万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 37.25万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 37.25万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 37.25万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 37.25万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 37.25万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 37.25万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 37.25万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 37.25万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 37.25万 - 项目类别:
Research Grant